uniQure (QURE) news
Recent news
Uniqure N.V.: Barclays cuts to equal-weight from overweight; cuts target price to $110 from $121
Barclays has revised its rating for Uniqure N.V. (UNQR), downgrading the stock from "overweight" to "equal-weight," while also lowering its target price to $110 from a previous estimate of $121. The adjustment reflects a reassessment of the company’s near-term outlook and market positioning,…
AInvest Wire · Oct 6, 2026Uniqure N.V.: RBC cuts target price to $48 from $65
AInvest Wire · Oct 2, 2026US-listed shares of Uniquure down 40% after co's Huntington's gene therapy fails to significantly slow disease progression in study
US-listed shares of UniQure (QURE) fell approximately 40% following the release of topline results from its gene therapy AMT-130 trial for Huntington’s disease, which failed to demonstrate slowing of disease progression in the overall study population. The therapy, which had previously shown…
AInvest Wire · Sep 29, 2026Uniqure shares fall 42% at open, most since March
AInvest Wire · Sep 29, 2026Uniquure N.V. - Mean CSF NFL 6% below baseline at 36 months for 14 high-dose patients
uniQure N.V. (NASDAQ: QURE) has reported updated data from its ongoing Phase I/II clinical trials of AMT-130, a gene therapy candidate for Huntington’s disease. As of the latest analysis, 14 patients who received the high dose of AMT-130 demonstrated a mean cerebrospinal fluid (CSF) neurofilament…
AInvest Wire · Sep 29, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.